In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Featured Clinical Trials Supported by the National Cancer Institute


Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.

To find other cancer trials open to enrollment:

  • Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
  • Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
  • For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
Comparing Postoperative Radiation Therapies for Brain Metastases
(Posted: 12/13/2011) - In this clinical trial, patients with one to four brain metastases who have had at least one of the metastatic tumors removed surgically will be randomly assigned to undergo whole-brain radiation therapy or stereotactic radiosurgery.

Cetuximab and Radiotherapy for HPV-Associated Oropharynx Cancer
(Posted: 11/01/2011) - In this clinical trial, patients with HPV-positive oropharyngeal squamous cell carcinoma will be randomly assigned to receive cisplatin chemotherapy plus intensity-modulated radiation therapy (IMRT) or the EGFR-targeted antibody cetuximab plus IMRT.

Bortezomib and Chemotherapy for Systemic Light-Chain Amyloidosis
(Posted: 10/18/2011) - In this trial, patients with previously untreated systemic light-chain amyloidosis will be randomly assigned to receive melphalan and dexamethasone with or without bortezomib. Doctors will assess the overall hematologic response rates to these chemotherapy regimens, as well as organ responses.

Testing Adjuvant Ipilimumab in Advanced Melanoma
(Posted: 10/04/2011) - In this clinical trial, patients with stage III or stage IV melanoma that has been completely resected will be randomly assigned to receive adjuvant (post-surgical) treatment with either ipilimumab or high-dose interferon alfa-2b, the current standard of care.

Studying the Natural Course of Precursor Conditions to Multiple Myeloma
(Posted: 09/20/2011) - Doctors at NCI will examine people previously diagnosed with MGUS or smoldering myeloma when they enroll in the study, after 6 months, and every 12 months for up to 5 years to identify risk factors or molecular markers that reliably predict which people will progress to full-blown multiple myeloma.

< Previous  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  Next >